In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion Pharmaceuticals Inc.

www.alexionpharma.com

Latest From Alexion Pharmaceuticals Inc.

Co-Pay Charity Settles Charges It Conspired With Teva, Biogen, Novartis On Kickbacks

The Assistance Fund directed donations received from the companies to patients taking their multiple sclerosis drugs, the US Department of Justice announced. Further settlements may be pending.

Compliance Legal Issues

Zealand Pharma Preps Pipeline For Catalyst-Filled 2020

Zealand Pharma’s recently installed CEO says it is building US operations to prepare for four potential approvals there in 2020, with commercial launches starting in 2021, its first ever.

Companies Research & Development

Welcome To Alexion 2.0

In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to preempt the Soliris-shaped hole in its balance sheet.

C-Suite Speaks Outlook 2020

Keeping Track: Industry Beefs Up 2020 Review Pipeline With Submissions Galore

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Drug Review
See All

Company Information

UsernamePublicRestriction

Register